Article
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Journal of gastroenterology - 1 Jan 2019
Takehara Tetsuo, Sakamoto Naoya, Nishiguchi Shuhei, Ikeda Fusao, Tatsumi Tomohide, Ueno Yoshiyuki, Yatsuhashi Hiroshi, Takikawa Yasuhiro, Kanda Tatsuo, Sakamoto Minoru, Tamori Akihiro, Mita Eiji, Chayama Kazuaki, Zhang Gulan, De-Oertel Shampa, Dvory-Sobol Hadas, Matsuda Takuma, Stamm Luisa M, Brainard Diana M, Tanaka Yasuhito, Kurosaki Masayuki
Abstract excerpt
BACKGROUND: In Japan, hepatitis C virus (HCV)-infected patients with decompensated cirrhosis currently have no treatment options. In this Phase 3 study, we evaluated sofosbuvir-velpatasvir with or without ribavirin for 12 weeks in patients with any HCV genotype and decompensated cirrhosis [Child-Pugh-Turcotte (CPT) class B or C] in Japan. METHODS: Patients were randomized 1:1 to receive sofosbuvir-velpatasvir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.